Newsroom - Alvotech - Better Access Better Lives

Skip Navigation

Alvotech

Latest news

Transactions of Managers and Closely Associated Persons

Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio®

Alvotech announces resubmission of U.S. Biologics License Applications for AVT05, a proposed biosimilar to Simponi® and Simponi Aria®, and AVT06, a proposed biosimilar to Eylea®

Media Contact

Benedikt Stefansson

Director of Investor Relations and Global Communications

Phone +354 422 4500

Connect on Linkedin

Media Gallery

Download center for company logos and images

Alvotech 2022. All rights reserved.